Cytek Biosciences, Inc.
CTKBCytek Biosciences is a leading cell analysis solutions company that develops next-generation research and clinical tools for biomedical research and clinical applications.
Earnings
Q3 2026 report
November 4, 2026Next report
Date not yet announcedValuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Cytek Biosciences is a leading cell analysis solutions company that develops next-generation research and clinical tools for biomedical research and clinical applications. The company utilizes its proprietary Full Spectrum Profiling (FSP) technology to provide high-resolution, high-content single-cell analysis by leveraging fluorescence signatures from multiple lasers. Its platform enables scientists to phenotype and isolate rare cell populations with high sensitivity, addressing limitations in conventional flow cytometry.
A leading innovator in spectral flow cytometry that differentiates itself through high-parameter multiplexing and superior sensitivity at a lower cost for performance compared to legacy systems.
FAQ
- What is Cytek Biosciences, Inc.'s market cap?
- Cytek Biosciences, Inc. (CTKB) has a market capitalization of $770.3M and trades on NASDAQ.
- What is Cytek Biosciences, Inc.'s revenue and profitability?
- Cytek Biosciences, Inc. generated $207.6M in trailing twelve-month revenue with a net loss of $81.2M, representing a net margin of -39.1%. Gross margin stands at 54.7%, with free cash flow of -$13.5M. The latest reported period is Q3 2026.
- Who are Cytek Biosciences, Inc.'s competitors?
- Cytek Biosciences, Inc.'s key competitors include Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific, and others. These companies compete in similar markets and product categories.
- What subsidiaries does Cytek Biosciences, Inc. have?
- Cytek Biosciences, Inc.'s subsidiaries include Amnis, Guava.
- Where is Cytek Biosciences, Inc. headquartered?
- Cytek Biosciences, Inc. is headquartered in United States of America and employs approximately 637 people. It has been publicly traded since 2021.
